Although transcription-factor defined subtypes (ASCL1, NEUROD1, POU2F3, and the inflamed SCLC-I group) have been described and show distinct therapeutic sensitivities, these profiles remain investigational and are not used in clinical practice [6]. Here, ASCL1 is linked to small cell lung carcinoma.